| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Department of Medical Oncology, Dana-Farber Cancer Institute; 2 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Requests for reprints: Geoffrey I. Shapiro, Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 810A, 44 Binney Street, Boston, MA 02115. Phone: 617-632-4942; Fax: 617-632-1977; E-mail: geoffrey_shapiro{at}dfci.harvard.edu.
Selective cyclin-dependent kinase (cdk) 2 inhibition is readily compensated. However, reduced cdk2 activity may have antiproliferative effects in concert with other family members. Here, inducible RNA interference was used to codeplete cdk2 and cdk1 from NCI-H1299 nonsmall cell lung cancer and U2OS osteosarcoma cells, and effects were compared with those mediated by depletion of either cdk alone. Depletion of cdk2 slowed G1 progression of NCI-H1299 cells and depletion of cdk1 slowed G2-M progression in both cell lines, with associated endoreduplication in U2OS cells. However, compared with the incomplete cell cycle blocks produced by individual depletion, combined depletion had substantial consequences, with G2-M arrest predominating in NCI-H1299 cells and apoptosis the primary outcome in U2OS cells. In U2OS cells, combined depletion affected RNA polymerase II expression and phosphorylation, causing decreased expression of the antiapoptotic proteins Mcl-1 and X-linked inhibitor of apoptosis (XIAP), effects usually mediated by inhibition of the transcriptional cdk9. These events do not occur after individual depletion of cdk2 and cdk1, suggesting that reduction of cdk2, cdk1, and RNA polymerase II activities all contribute to apoptosis in U2OS cells. The limited cell death induced by combined depletion in NCI-H1299 cells was significantly increased by codepletion of cdk9 or XIAP or by simultaneous treatment with the cdk9 inhibitor flavopiridol. These results show the potency of concomitant compromise of cell cycle and transcriptional cdk activities and may guide the selection of clinical drug candidates. (Cancer Res 2006; 66(18): 9270-80)
This article has been cited by other articles:
![]() |
P. Bonvini, E. Zorzi, L. Mussolin, G. Monaco, M. Pigazzi, G. Basso, and A. Rosolen The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity Haematologica, July 1, 2009; 94(7): 944 - 955. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Eguchi, H. Itadani, T. Shimomura, N. Kawanishi, H. Hirai, and H. Kotani Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines Mol. Cancer Ther., June 1, 2009; 8(6): 1460 - 1472. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Scholz, K Wagner, M Welzel, F Remlinger, B Wiedenmann, G Siemeister, S Rosewicz, and K M Detjen The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model Gut, February 1, 2009; 58(2): 261 - 270. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Squires, R. E. Feltell, N. G. Wallis, E. J. Lewis, D.-M. Smith, D. M. Cross, J. F. Lyons, and N. T. Thompson Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines Mol. Cancer Ther., February 1, 2009; 8(2): 324 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bettayeb, O. M. Tirado, S. Marionneau-Lambot, Y. Ferandin, O. Lozach, J. C. Morris, S. Mateo-Lozano, P. Drueckes, C. Schachtele, M. H.G. Kubbutat, et al. Meriolins, a New Class of Cell Death Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases Cancer Res., September 1, 2007; 67(17): 8325 - 8334. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Berthet, M. C. Rodriguez-Galan, D. L. Hodge, J. Gooya, V. Pascal, H. A. Young, J. Keller, R. Bosselut, and P. Kaldis Hematopoiesis and Thymic Apoptosis Are Not Affected by the Loss of Cdk2 Mol. Cell. Biol., July 15, 2007; 27(14): 5079 - 5089. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chen, Y. Dai, H. Harada, P. Dent, and S. Grant Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax Translocation Cancer Res., January 15, 2007; 67(2): 782 - 791. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |